133 related articles for article (PubMed ID: 16917207)
1. Synergistic antimyeloma effects of zoledronate and simvastatin.
Schmidmaier R; Simsek M; Baumann P; Emmerich B; Meinhardt G
Anticancer Drugs; 2006 Jul; 17(6):621-9. PubMed ID: 16917207
[TBL] [Abstract][Full Text] [Related]
2. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.
Schmidmaier R; Baumann P; Bumeder I; Meinhardt G; Straka C; Emmerich B
Eur J Haematol; 2007 Sep; 79(3):240-3. PubMed ID: 17655704
[TBL] [Abstract][Full Text] [Related]
3. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
Baumann P; Armann J; Mandl-Weber S; Grün G; Oduncu F; Schmidmaier R
Eur J Haematol; 2008 Jan; 80(1):37-45. PubMed ID: 18028419
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Cheng YY; Huang L; Lee KM; Xu JK; Zheng MH; Kumta SM
Calcif Tissue Int; 2004 Jul; 75(1):71-7. PubMed ID: 15037971
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway.
Schmidmaier R; Mandl-Weber S; Gaul L; Baumann P; Bumeder I; Straka C; Emmerich B
Int J Oncol; 2007 Oct; 31(4):969-76. PubMed ID: 17786331
[TBL] [Abstract][Full Text] [Related]
8. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
[TBL] [Abstract][Full Text] [Related]
9. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
10. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
11. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
Koizumi M; Nakaseko C; Ohwada C; Takeuchi M; Ozawa S; Shimizu N; Cho R; Nishimura M; Saito Y
Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213
[TBL] [Abstract][Full Text] [Related]
14. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Derenne S; Amiot M; Barillé S; Collette M; Robillard N; Berthaud P; Harousseau JL; Bataille R
J Bone Miner Res; 1999 Dec; 14(12):2048-56. PubMed ID: 10620064
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
18. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G
Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
20. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
